|Dr. Mark Pruzanski||Founder, CEO, Pres & Director||1.3M||4.42M||1968|
|Mr. Sandip S. Kapadia CPA, M.B.A.||CFO, Treasurer & Principal Accounting Officer||738.4k||N/A||1970|
|Mr. Jerome B. Durso||Chief Operating Officer||953.9k||N/A||1968|
|Mr. Ryan T. Sullivan||Gen. Counsel & Sec.||733.98k||278.78k||1976|
|Mr. Richard Kim||Pres of U.S. Commercial & Strategic Marketing||987.56k||N/A||1969|
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Intercept Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 5. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 6; Compensation: 5.